Your browser doesn't support javascript.
loading
Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation.
Wu, Hengwei; Cai, Zhen; Shi, Jimin; Luo, Yi; Huang, He; Zhao, Yanmin.
Afiliação
  • Wu H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.
  • Cai Z; Institute of Hematology, Zhejiang University Hangzhou, Zhejiang Province, China.
  • Shi J; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy Hangzhou, Zhejiang Province, China.
  • Luo Y; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center Hangzhou, Zhejiang Province, China.
  • Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang Province, China.
  • Zhao Y; Institute of Hematology, Zhejiang University Hangzhou, Zhejiang Province, China.
Am J Cancer Res ; 11(6): 3111-3122, 2021.
Article em En | MEDLINE | ID: mdl-34249448
Loss of patient-specific HLA after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is considered as a relapse mechanism for lacking the incompatible molecule to elicit alloreactivity, which extensively diminishing graft-versus-leukemia (GVL) effects. Blinatumomab, as a CD3/CD19 bispecific antibody, can yield a profound response via redirecting T cells towards malignant lymphoblasts in B-cell acute lymphoblastic leukemia (B-ALL). We aimed to assess the feasibility of blinatumomab in treating patients with HLA loss relapse after haplo-HSCT. Four eligible patients undergoing HLA loss relapse after haplo-HSCT were enrolled in the study. Four patients achieved a complete remission/complete remission with partial he-matologic recovery (CR/CRh) with three minimal residual disease (MRD)-negative response within the first cycle of treatment. Three of the four met a primary endpoint with CR/CRh and MRD-negative response within 2 cycles of treatment. One patient developed new extramedullary sites of skin after the first cycle. Cytokine release syndrome was observed in one patient. Cytopenias, as well as elevated alanine aminotransferase and aspartate aminotransferase, were two common adverse effects during treatment. By redirecting lysis of CD19-positive lymphoblast who losing the incompatible HLA, blinatumomab is a potential strategy to eradicate malignant cells via restoring GVL effects. A randomized clinical trial assessing blinatumomab in patients with HLA loss relapse after HSCT is warranted.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Am J Cancer Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Am J Cancer Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos